10 Best Biotech Stocks Under $10 to Buy

Page 1 of 5

Biotechnology stocks have delivered strong gains in 2026, supported by encouraging clinical trial results, regulatory approvals, and growth in drug sales. Investors’ appetite for high-growth companies has also edged higher, as depicted by the S&P 500 biotechnology sector gaining 31% year-to-date, in line with the Insider Monkey Billionaire Index‘s gain. Advances in drug development for cancer and genetic disorders have also strengthened investor sentiment in the sector.

In addition to strong investor interest, a surge in merger and acquisition deals has also supported the rally. As major pharmaceutical companies seek to replenish their drug pipelines and offset revenue losses from patent expirations, many have turned to smaller firms developing promising therapies.

Deal activity has largely focused on companies developing treatments in obesity, immunology, inflammation, oncology, and rare diseases. According to Reuters, deal-making is on course for a bumper year after hitting $84 billion in the first quarter as large drug makers look to boost their pipelines.

Deal-making continued to gain momentum in the first half of the year, with transactions totaling approximately $117.7 billion. Notable deals include Sun Pharmaceutical’s $12.6 billion acquisition of Organon and Eli Lilly’s $8.1 billion deal for Centessa Pharmaceutical.

10 Best Biotech Stocks Under $10 to Buy

Source:unsplash

According to Moody’s, pharmaceutical companies had close to $175 billion in cash and free cash flow to pursue acquisitions. Meanwhile, smaller biotechnology firms have faced greater financing challenges in a high-interest-rate environment. That’s because they rely on external financing while developing medicines, which can be expensive as interest rates rise.

Against this backdrop, initial public offering activity in the sector has also slowed. The slowdown comes as investors increasingly demand evidence of clinical progress and commercial potential before committing capital to newly listed businesses.

Some of the subsectors with the strongest growth outlook include oncology, where demand for cancer treatments and targeted therapies remains strong. Obesity and metabolic disease also present strong commercial opportunities. Goldman Sachs expects global obesity sales to increase 15% to $114 billion.

Artificial intelligence is another emerging growth driver given its potential to improve research productivity and identify promising drug candidates. Check out these popular hedge funds healthcare stocks benefiting from AI use in drug development.

Small biotechnology stocks have participated in the broader rally in 2026, but performance is highly uneven. Stocks trading below $10 may attract investors seeking exposure to emerging therapies and potential clinical or regulatory catalysts at relatively low share prices. Take a look at some of the cheap biotech stocks on valuation.

For investors, the most compelling candidates have credible clinical programs, enough cash to fund upcoming milestones, differentiated treatment candidates, and a realistic path to commercialization.

Our Methodology

For this article, we used stock screeners to identify biotechnology stocks with market capitalizations above $1 billion. We then focused on stocks trading below $10 and popular among elite hedge funds in Q2 2026. From this group, we selected 10 stocks and ranked them in ascending order by the number of hedge funds holding stakes.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10. Immatics N.V. (NASDAQ:IMTX)

Number of Hedge Fund Holders: 26

Market Capitalization as of October 27: $1.11 Billion

Share Price as of October 27: $7.26

Immatics N.V. (NASDAQ:IMTX) has declined approximately 30% year to date, retreating from its all-time highs despite continued progress in developing targeted cancer immunotherapies. The pullback could present an opportunity for investors seeking exposure to the biotechnology company’s clinical pipeline at a discount.

On October 13, Stifel initiated coverage of the stock with a Buy rating and a $15 price target. According to the research firm, the company is well positioned to lead in melanoma with its PRAME-HLA complex-directed autologous cell therapy, Anzu-cel. See how the drug’s progress has been year-to-date.

The candidate has demonstrated encouraging antitumor activity across multiple indications, with a confirmed objective response rate of 56%, supporting its potential as a treatment option for patients with advanced cancers.

Immatics N.V. is also developing IMA203CD8 to expand treatment options for PRAME-positive cancers, including difficult-to-treat gynecologic cancers. The drug achieved a 63% objective response rate and 50% confirmed response rate in its reported gynecologic-cancer dataset. Read what analysts are saying on positive trials.

As of the end of the second quarter, Immatics had $448.2 million in cash and other financial assets, giving it financial flexibility to develop its pipeline as it also prepares for a potential product launch.

While clinical and regulatory risks remain, encouraging response data, a well-funded development program, and a favorable analyst outlook make Immatics a biotechnology stock worth watching for investors seeking exposure to emerging cancer immunotherapies.

9. Precigen, Inc. (NASDAQ:PGEN)

Number of Hedge Fund Holders: 27

Market Capitalization as of October 27: $2.20 Billion

Share Price as of October 27: $6.15

Precigen, Inc. (NASDAQ:PGEN) has outperformed the broader market, supported by significant commercial and regulatory progress across its gene and cell therapy platform. Up about 46% year to date, the stock has outperformed the Insider Monkey Billionaire Index and the S&P 500 Biotech index, which are up about 31%.

Its edge as one of the best biotech stocks under $10 to buy stems from the successful commercial launch of PAPZIMEOS. Recurrent respiratory papillomatosis (RRP) treatment generated about $74.7 million in revenue in the first half of 2026, with second-quarter sales more than doubling. The company also returned to profitability in the second quarter, with net income of $20.1 million compared to a net loss of $26.6 million a year ago.

The strong commercial performance has strengthened the company’s position as a revenue-generating biotechnology company rather than one dependent solely on clinical milestones. What does commercial launch success mean?

PAPZIMEOS being the only FDA-approved treatment for adults with RRP gives Precigen a differentiated commercial position in a market where patients have historically faced recurring procedures to manage the disease. It’s already seeking regulatory approval in Europe to expand the drug’s revenue opportunity.

Additionally, Precigen, Inc. has been flying high after the FDA granted the company platform technology designation for its AdenoVerse’s immunotherapy platform. The designation could provide regulatory and development advantages for eligible products, potentially supporting more efficient development and review processes.

The drug’s sales momentum, regulatory exclusivity, and potential expansion into Europe have strengthened Precigen’s investment thesis.

Page 1 of 5